Responses
Poster Presentations
Psoriatic arthritis
FRI0463 Secukinumab Improves Minimal Disease Activity Response Rates in Patients with Active Psoriatic Arthritis: Data from The Randomized Phase 3 Study, Future 2
Compose a Response to This Article
Other responses
No responses have been published for this article.